May 9, 2012
Mitsubishi Tanabe Pharma Corporation (MTPC) announced on May 7 that the US venture company VIVUS, Inc., a licensee of its PDE5 (phosphodiesterase type 5) inhibitor TA-1790 (avanafil) developed for the treatment of erectile dysfunction (ED), received approval for the drug...read more